Literature review reveals diverse manifestations and recurrence risks of giant cell tumors in different anatomical locations, suggesting the need for targeted therapies.
Key Points
Giant cell tumors, although typically benign, can exhibit aggressive growth and a risk of recurrence, particularly in various anatomical sites.
The H3F3A mutation serves as a key diagnostic marker for giant cell tumors found in long bones, prevalent in individuals aged 20–40 years.
Therapeutic modalities for giant cell tumors vary in effectiveness and include both conservative and operative approaches depending on tumor location and characteristics.
Increased CSF1 expression due to genetic translocation is noted in giant cell tumors of tendons, which predominantly affect women aged 30–50 years.